about
Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosisTreatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis.DNA-based vaccines for multiple sclerosis: current status and future directions.Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation.Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies.DNA Vaccination Techniques.Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.Circulating EZH2-positive T cells are decreased in multiple sclerosis patientsExome sequencing study in patients with multiple sclerosis reveals variants associated with disease courseCerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosisMonocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigenDNA vaccines prime CD8+ T cell responses to epitopes of viral antigens produced from overlapping reading frames of a single coding sequenceLevels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosisReplyDetection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
P50
Q34008878-AD51BB90-139D-4AC1-9CCD-06A723462529Q34714531-F734340C-F5ED-4832-9D6F-2E6A1F3FA424Q35177161-0D737C3A-B67D-4B3A-ABF3-8B0BC9E3C2F3Q36299378-121754BA-C13A-486D-9955-87BA9D0CFEF7Q37821598-7F97807B-38A5-4B61-92FC-21AF0C76FF48Q40263853-99C9EC67-7C9D-4E22-B6DF-8F0F54098C17Q42232030-FD5F34A3-76E5-4D67-8479-627FFF8713A0Q46367467-896DFB48-030F-4DAA-B9B4-B5463212DC73Q46790535-FD636A14-B1C9-44B7-A6B0-17FFE59DAB0EQ48690365-E4DC8043-6458-43CE-BC0C-7EAB9827EED6Q50543805-5F5A918C-F87D-4780-ADCA-1B314300C6A4Q50692674-A5B1B616-8D05-49F8-B582-F9725BEF90FDQ54342319-24AE6A44-A10C-4B92-8369-D42EB2518300Q58115047-3FE955FB-CE99-4C29-A90A-1F6F07E4E215Q58740519-503D7C78-5872-4ACD-9938-5437D1BC391FQ59847246-1617467E-6E26-4AA1-B69B-36DF7982BEC0Q64889510-05CEF982-41B7-4DE1-8F60-ED790C7D3CF5Q73852033-C562BE2D-C9CB-4C58-B216-09E8F568500BQ81128868-3BD470D0-0F73-4B12-BB57-D2033DFA0779Q87807704-B08938D1-D2FD-44F3-B98A-CEFE85ADB659Q88905456-AD85C77A-7A78-4921-9356-C38EF04D0DEDQ93188558-4C890D6C-8EFE-40CB-A17A-DB2D32B48448
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7701-9346
@en
name
Nicolás Fissolo
@ast
Nicolás Fissolo
@en
Nicolás Fissolo
@es
Nicolás Fissolo
@nl
type
label
Nicolás Fissolo
@ast
Nicolás Fissolo
@en
Nicolás Fissolo
@es
Nicolás Fissolo
@nl
prefLabel
Nicolás Fissolo
@ast
Nicolás Fissolo
@en
Nicolás Fissolo
@es
Nicolás Fissolo
@nl
P106
P1153
6506394852
P21
P31
P496
0000-0002-7701-9346